<DOC>
	<DOCNO>NCT02517359</DOCNO>
	<brief_summary>RV6153 new medicine develop possible treatment asthma smoke related lung disease ( also know chronic obstructive pulmonary disease - COPD ) . The main purpose study investigate safety , tolerability , pharmacokinetics pharmacodynamics single repeat dos RV6153</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Repeat Doses RV6153</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Cohorts 1 13 ( subject ) Subject must man woman age 18 65 year age , inclusive : Women nonchildbearing potential define amenorrhoeic great 1 year appropriate clinical profile permanently sterilise . Men willing able use suitable contraception method list Section 4.5.1 , time first dose study medication 90 day discharge study . A woman must negative serum β human chorionic gonadotropin ( βhCG ) test screen negative urine pregnancy test Day 1 . Subject must willing able adhere prohibition restriction specify protocol Each subject must sign informed consent form ( ICF ) Body weight ≥50 kg BMI within range 1929 kg/m2 ( inclusive ) . Average QTcF &lt; 450 msec screen Day 1 visit Vital sign assessment within normal range . Cohorts 1 11 13 ( healthy volunteer smoker ) Healthy determine physician , base full medical evaluation include medical history , physical examination , laboratory test . Spirometry reading ( FEV1 FVC ) ≥80 % predict value FEV1/FVC ratio &gt; 0.7 screening . Cohort 12 ( asthma patient ) Documented history asthma , first diagnose least 6 month prior screen visit . Currently treat daily standard care asthma therapy Have diagnosis asthma confirm screen bronchodilator reversibility . Have stable asthma base physician assessment screen prior randomisation , asthma exacerbation require augmentation therapy 12 week prior screen hospitalization visit accident emergency asthma 12 month prior screen . Have prebronchodilator force expiratory volume first second ( FEV1 ) ≥60 % ≤85 % predict normal value screen . Subject must otherwise healthy basis full medical evaluation perform screen . Cohort 13 ( smoker ) Subjects current daily cigarette smoker . Cohorts 1 13 ( subject ) Upper low respiratory tract infection within 4 week screen visit prior randomisation . A positive prestudy hepatitis B surface antigen positive hepatitis C antibody result screen . Current chronic history liver disease , know hepatic biliary abnormality . Positive test alcohol drug abuse . Use prescription medication within 14 day prior screen visit agree use prescription medication throughout duration study . Are take counter ( OTC ) medication 14 day prior Screening visit agree refrain taking medication throughout study . History regular alcohol consumption within 6 month study Definite suspected history drug alcohol abuse within previous 5 year . A positive test HIV antibody . Received experimental drug use experimental medical device within 3 month within period less five time drug 's halflife first dose study drug schedule . Allergy active inactive ingredient ( include lactose milk protein intolerance ) study medication . History drug , allergy would contraindicate participation . A disclosed history one know Investigator , significant noncompliance previous investigational study prescribe medication . Donated blood blood product substantial loss blood ( 500 mL ) within 3 month first administration study drug intention donate blood blood product study . Subject mentally legally incapacitate . Subject employee Sponsor contract research organization ( CRO ) , relative employee Sponsor CRO . Unable unwilling undergo multiple venipuncture procedure subject poor access vein suitable cannulation . Any reason Investigator considers make subject unsuitable participate . Cohorts 1 11 ( healthy subject ) Any acute chronic illness clinically relevant abnormality identify screen medical assessment . The subject smoker smoke use nicotinecontaining product ( include ecigarettes nicotine contain product ) within 6 month prior screen smoke history ≥5 pack year . Positive urine cotinine test screen visit indicative smoking use tobacco nicotinecontaining product . Cohort 12 ( asthma patient ) Has ever episode lifethreatening asthma define respiratory arrest , intubation asthma , ICU admission asthma Has hospitalize great 24 hour due asthma 5 year prior study . Has experience asthma exacerbation 3 month prior screen ( prior randomisation ) require management systemic injectable steroid . Has uncontrolled ( severe ) asthma and/or use study prohibit asthma medication . The subject smoker ( regular irregular ) , smoke use nicotinecontaining product ( include ecigarettes ) within 6 month prior screen ( smoke history ≥10 pack year ) . Positive urine cotinine test screen visit , Day 1 , indicative smoking use tobacco nicotinecontaining product . Cohort 13 ( smoker ) Any acute chronic illness , include diagnosis COPD , clinically relevant abnormality identify screen medical assessment . Subjects unable produce viable sputum sample screen Subjects whose primary consumption tobacco via method cigarette . Primary method tobacco consumption exclude include , limited pipe , cigar ecigarettes . Urinary cotinine level screen &lt; 30 nanogram ( ng ) /mL . Subjects asthma history asthma ( except childhood remit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>